Severe COVID-19 Clinical Trial
Official title:
Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19: Electronic Survey (ASAP-C Study)
Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndrome(SARS-Co-2) infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS), despite previous data and clinical practice for patients with refractory or severe form of ARDS.
Administration of systemic corticosteroids for patients with severe forms of SARS-Co-2 infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for patients with refractory or severe form of ARDS. But at the latest after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July 2020) and ensued metaanalysis of World Health Organization (WHO) working group, the routine administration of systemic corticosteroids was revisited. However, there are ongoing critical debate of the evidence regarding the dose, administration, timing and type of corticosteroids and ongoing randomized controlled trial (RCT) are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. The dynamic of COVID-19 surges, flip-flop of official recommendations within very short period of time and ongoing critical debate could be with possible variations of daily clinical practice regarding using systemic corticosteroids. In an electronic evaluation form that will be send to European Society of Intensive Care (ESICM) Members. The electronic survey will contain 10 question. In the questionnaire the participants will have to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05175833 -
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
|
Phase 2 | |
| Recruiting |
NCT05256511 -
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
|
||
| Completed |
NCT04866082 -
Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
|
||
| Active, not recruiting |
NCT04918901 -
Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
|
||
| Recruiting |
NCT05233605 -
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
|
||
| Not yet recruiting |
NCT04613986 -
Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
|
N/A | |
| Recruiting |
NCT05447013 -
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04733833 -
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
|
Phase 2 | |
| Recruiting |
NCT04712344 -
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)
|
Phase 2 | |
| Terminated |
NCT04713176 -
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
|
Phase 3 | |
| Enrolling by invitation |
NCT06235866 -
Risk Identification of Long-term Complications
|
||
| Recruiting |
NCT05254990 -
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT05596617 -
Safety and Efficacy of Medications COVID-19
|
N/A |